within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BX02_Sucralfate;

model Sucralfate
  extends Pharmacolibrary.Drugs.ATC.A.A02BX02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A02BX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sucralfate is a cytoprotective agent used primarily to treat and prevent ulcers in the gastrointestinal tract, especially duodenal ulcers. It acts locally by forming a protective barrier at ulcer sites and does not have significant systemic absorption. Sucralfate is currently approved and widely used for gastroduodenal ulcer management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults administered standard oral doses, based on available pharmacological knowledge and product labels indicating minimal systemic absorption.</p><h4>References</h4><ol><li><p>Urzúa, N, et al., &amp; Errecalde, C (2020). Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 50(12) 1490–1493. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2020.1793031&quot;>10.1080/00498254.2020.1793031</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32628058/&quot;>https://pubmed.ncbi.nlm.nih.gov/32628058</a></p></li><li><p>KuKanich, K, et al., &amp; Heinrich, E (2014). Effect of sucralfate on oral minocycline absorption in healthy dogs. <i>Journal of veterinary pharmacology and therapeutics</i> 37(5) 451–456. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12116&quot;>10.1111/jvp.12116</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24611544/&quot;>https://pubmed.ncbi.nlm.nih.gov/24611544</a></p></li><li><p>KuKanich, K, &amp; KuKanich, B (2015). The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. <i>Journal of veterinary pharmacology and therapeutics</i> 38(2) 169–173. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12165&quot;>10.1111/jvp.12165</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25233871/&quot;>https://pubmed.ncbi.nlm.nih.gov/25233871</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Sucralfate;
